Hanna, Catherine R.Robles Zurita, José A.Briggs, AndrewHarkin, AndreaKelly, CarolineMcQueen, JohnAllan, KarenPearson, SarahHollander, HenrikGlimelius, BengtSalazar Soler, RamónSegelov, EvaSaunders, MarkIveson, TimJones, Robert J.Boyd, Kathleen A.2021-09-172021-09-172021-09-011533-0028https://hdl.handle.net/2445/180102Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and methods: Individual cost-utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost-utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial.9 p.application/pdfengcc by (c) Hanna, Catherine R. et al, 2021http://creativecommons.org/licenses/by/3.0/es/Càncer colorectalEconomia de la salutCancer chemotherapyMedical economicsinfo:eu-repo/semantics/article2021-09-16info:eu-repo/semantics/openAccess33992542